Alvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET
Alvotech (NASDAQ: ALVO), a global biotech company focused on biosimilar medicines, has announced its schedule for reporting financial results for the first half of 2024. The company will release its financial results on August 15, 2024, after U.S. markets close. Following this, Alvotech will host a conference call on August 16, 2024, at 8:00 am EDT (12 noon GMT) to present the financial results and recent business highlights to analysts.
The conference call will be accessible via webcast to news media, investors, and the general public. Details for accessing the webcast or participating in the conference call are available on Alvotech's investor website. A replay of the webcast will be archived and available for 90 days after the event.
Alvotech (NASDAQ: ALVO), un'azienda biotech globale focalizzata su medicinali biosimilari, ha annunciato il suo programma per la comunicazione dei risultati finanziari per il primo semestre del 2024. L'azienda pubblicherà i risultati finanziari il 15 agosto 2024, dopo la chiusura dei mercati statunitensi. Successivamente, Alvotech ospiterà una chiamata congiunta il 16 agosto 2024, alle 8:00 EDT (12:00 GMT) per presentare i risultati finanziari e i recenti punti salienti aziendali agli analisti.
La chiamata sarà disponibile tramite webcast per i media, gli investitori e il pubblico generale. I dettagli per accedere al webcast o partecipare alla chiamata sono disponibili sul sito web per gli investitori di Alvotech. Una registrazione del webcast sarà archiviata e disponibile per 90 giorni dopo l'evento.
Alvotech (NASDAQ: ALVO), una empresa biotecnológica global centrada en medicamentos biosimilares, ha anunciado su cronograma para informar sobre resultados financieros para la primera mitad de 2024. La compañía publicará sus resultados financieros el 15 de agosto de 2024, después del cierre de los mercados en EE. UU. A continuación, Alvotech realizará una llamada de conferencia el 16 de agosto de 2024, a las 8:00 am EDT (12:00 GMT) para presentar los resultados financieros y los aspectos más destacados del negocio reciente a los analistas.
La llamada de conferencia será accesible a través de un webcast para los medios de comunicación, inversores y el público en general. Los detalles para acceder al webcast o participar en la llamada de conferencia están disponibles en el sitio web de inversores de Alvotech. Una repetición del webcast se archivará y estará disponible durante 90 días después del evento.
알보텍(NASDAQ: ALVO)은 바이오시밀러 의약품에 집중하는 글로벌 생명공학 회사로서 2024년 상반기 재무 결과 발표 일정을 발표했습니다. 이 회사는 2024년 8월 15일에 미국 시장 마감 후 재무 결과를 발표할 예정입니다. 이후 알보텍은 2024년 8월 16일 오전 8시 EDT (GMT 기준 오후 12시)에 분석가들에게 재무 결과 및 최근 사업 주요 사항을 발표하는 컨퍼런스 콜을 개최할 것입니다.
컨퍼런스 콜은 웹캐스트를 통해 접근할 수 있습니다 미디어, 투자자 및 일반 대중을 위해. 웹캐스트에 접근하거나 컨퍼런스 콜에 참여하기 위한 세부정보는 알보텍의 투자자 웹사이트에서 확인할 수 있습니다. 웹캐스트의 재생은 이벤트 후 90일 동안 아카이브되어 이용 가능할 것입니다.
Alvotech (NASDAQ: ALVO), une entreprise biopharmaceutique mondiale spécialisée dans les médicaments biosimilaires, a annoncé son calendrier pour la publication des résultats financiers du premier semestre 2024. L'entreprise publiera ses résultats financiers le 15 août 2024, après la fermeture des marchés américains. Par la suite, Alvotech organisera une conférence téléphonique le 16 août 2024, à 8h00 EDT (12h00 GMT) pour présenter les résultats financiers et les points forts commerciaux récents aux analystes.
La conférence téléphonique sera accessible via un webcast pour les médias, les investisseurs et le grand public. Les détails sur l'accès au webcast ou la participation à la conférence téléphonique sont disponibles sur le site Web des investisseurs d'Alvotech. Un enregistrement du webcast sera archivé et disponible pendant 90 jours après l'événement.
Alvotech (NASDAQ: ALVO), ein globales Biotechnologieunternehmen, das sich auf biosimilar Arzneimittel konzentriert, hat seinen Zeitplan zur Veröffentlichung der finanziellen Ergebnisse für das erste Halbjahr 2024 bekannt gegeben. Das Unternehmen wird am 15. August 2024 nach Schließung der US-Märkte seine finanziellen Ergebnisse veröffentlichen. Anschließend wird Alvotech am 16. August 2024 um 8:00 Uhr EDT (12:00 Uhr GMT) eine Telefonkonferenz abhalten, um die finanziellen Ergebnisse und aktuelle Geschäftshighlights den Analysten vorzustellen.
Die Telefonkonferenz wird über ein Webcast zugänglich sein für Medien, Investoren und die allgemeine Öffentlichkeit. Details zur Teilnahme am Webcast oder zur Teilnahme an der Telefonkonferenz sind auf der Investorenseite von Alvotech verfügbar. Eine Aufzeichnung des Webcasts wird archiviert und ist 90 Tage nach der Veranstaltung verfügbar.
- Timely financial reporting demonstrates transparency and compliance
- Hosting a conference call indicates open communication with investors and analysts
- None.
Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first half of the year ended June 30, 2024, after U.S. markets close on Thursday, August 15, 2024, and will conduct a conference call with analysts to present the financial results and recent business highlights on Friday August 16, 2024, at 8:00 am EDT (12 noon GMT).
Live audio of the conference call will also be webcast and available to members of the news media, investors, and the general public. Information on how to access the webcast or participate by conference call is posted on Alvotech’s investor website https://investors.alvotech.com. A direct link to the event is https://investors.alvotech.com/events/event-details/q2-2024-earnings. The webcast will also be archived and available for replay for 90 days after the event.
About Alvotech
Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products, and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech has launched two biosimilars. The current development pipeline includes nine disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. Alvotech’s commercial partners include Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. (US), STADA Arzneimittel AG (EU), Fuji Pharma Co., Ltd (Japan), Advanz Pharma (EEA, UK, Switzerland, Canada, Australia and New Zealand), Dr. Reddy’s (EEA, UK and US), Cipla/Cipla Gulf/Cipla Med Pro (Australia, New Zealand, South Africa/Africa), JAMP Pharma Corporation (Canada), Yangtze River Pharmaceutical (Group) Co., Ltd. (China), DKSH (Taiwan, Hong Kong, Cambodia, Malaysia, Singapore, Indonesia, India, Bangladesh and Pakistan), YAS Holding LLC (Middle East and North Africa), Abdi Ibrahim (Turkey), Kamada Ltd. (Israel), Mega Labs, Stein, Libbs, Tuteur and Saval (Latin America) and Lotus Pharmaceuticals Co., Ltd. (Thailand, Vietnam, Philippines, and South Korea). Each commercial partnership covers a unique set of product(s) and territories. Except as specifically set forth therein, Alvotech disclaims responsibility for the content of periodic filings, disclosures and other reports made available by its partners. For more information, please visit www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.
ALVOTECH INVESTOR RELATIONS AND GLOBAL COMMUNICATIONS
Benedikt Stefansson, VP
alvotech.ir@alvotech.com
Please visit our investor portal, and our website or follow us on social media on LinkedIn, Facebook, Instagram, X and YouTube.
FAQ
When will Alvotech (ALVO) release its financial results for the first half of 2024?
What time is Alvotech's (ALVO) earnings conference call for the first half of 2024?
How can investors access Alvotech's (ALVO) first half 2024 earnings call?
Will there be a replay available for Alvotech's (ALVO) first half 2024 earnings call?
